What Talphera (TLPH) Said on Its Q3 Earnings Call
Talphera (TLPH) discussed Q3 earnings, highlighting FDA submission details, increased peak-sales estimates, and cash position. The company expects $14.2M in cash and $16M in conditional financing to support operations through 2027. Expenses rose to $3.8M due to Niyad development and pre-launch activities. Talphera plans an investor event in Q1 2027 to discuss opportunities.






